Business Context and Reporting Period
This Form 6-K filing by Galmed Pharmaceuticals Ltd. covers the period ending March 5, 2026. The report documents the outcome of a Special General Meeting of Shareholders held on that date.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance events rather than financial performance.
Material Changes
There are no material financial changes reported in this document. The primary event is the successful shareholder vote on a proposal detailed in a proxy statement filed on February 9, 2026.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors. It confirms that the shareholder proposal was approved by the requisite majority in accordance with the Israeli Companies Law, 5759-1999.
Key Facts for Investors
- Shareholders approved the proposal presented at the Special General Meeting on March 5, 2026.
- The proposal details are contained in a proxy statement filed on February 9, 2026, which is referenced but not included in this text.
- No financial data or operational metrics are disclosed in this specific filing.